CONFERENCE CHAIR: Eric Bloome, Vice President, Global Pre-Clinical Safety Senior Research Fellow, AbbVie

SMi is delighted to announce the 13th annual ADMET conference returning to London on the 9th – 10th July 2018, featuring.

Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times.

The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14,319.9 Million by 2022, with a CAGR of 10.6% from 2016 to 2022*. The main objective of early prediction of ADME properties of a compound is to increase the success rate of it reaching the development stage.

*Source: http://bit.ly/2hMJcgU

This event is CPD accredited.

Speaker Line-Up includes: Pau Aceves, Peter Littlewood, Filipe Lopes, Andreas Reichel, Laurent Salphati, Timothy Schulz-Utermoehl, Kunal Taskar, Robert Van Waterschoot, Ian Wilson.

Early bird offers available!

For details and to register, visit the website at www.admet-event.com  or contact the team at +44(0) 207 827 6000, email ssapal@smi-online.co.uk